Toronto, ON – September 17-18, 2016
Living with chronic pain is a reality for countless people, both young and old. Many of the available pain relief options come in the form of narcotics or drugs with substantial side effects. While these options may help reduce the pain, the numerous side effects can be cause for great concern. With the advancements in pharmaceutical compounding, these people can now receive medication that is customized for their own unique needs in order to provide pain relief. Utilizing a number of different compounding solution options such as creams, gels, ointments, sprays, capsules and others, painful conditions can be managed in a fashion tailored to the individual needs of each patient.
This activity will provide participants with the opportunity to enhance their competency as it relates to the many therapeutic options used in analgesic therapies including compounding solution options. Having been presented with a prescription indicating a need for a compounded medication, the participant will use uniquely designed patient assessment tools, select appropriate delivery systems for the specific analgesics and nutritional supplements prescribed, and monitor patient progress. During this process, the participant will have learned how to:
- Relate drug mechanisms of action to physiological and pathophysiological pathways responsible for the elicitation of a pain response.
- How to conduct a patient needs analysis.
- Work with physicians to provide pharmacist expertise with respect to the therapeutic, concomitant adjuvant, and lifestyle and behavior modification options available to the physician.
Finally, participants will apply monitoring tools and strategies to maintain patient compliance with prescribed analgesic initiatives. Clinical case scenarios will be discussed and clinical findings recorded in a formal manner for purposes of confidential communication, record keeping, and statistical analysis.
Pharmacists engaged in prescription analgesic compounding.
American Physicians: Physicians, on their own accord, may assess this activity for its educational value and learning experience in order to determine if this activity is appropriate for claiming AMA PRA Category 2 Credits™ under the American Medical Association (AMA) Physician’s Recognition Award (PRA) and credit system.
Canadian Physicians: Physicians of the College of Family Physicians of Canada (CFPC) may be able to claim Mainpro-M2 credits for self-directed or non-CFPC-accredited learning activities (i.e., programs that are not Mainpro-M1 or Mainpro-C accredited).
We believe that a collaborative relationship between physicians and pharmacists is fundamental to providing patients with the personalized care needed to address their unique health need. Contact us now to receive a free registration to invite a physician1.
Use our invitation letter template to personally invite the physician of your choice.
1Physician and pharmacist training to be taken concurrently. Limit of one physician per registrant.
- Employ compounding principles and techniques of analgesic formulation-related delivery systems.
- Develop a novel targeting approach to physiological and pathophysiological pathways.
- Relate physiological and biochemical features of signal transmission and transduction.
- Interpret deleterious signal elicitation and subsequent excitation, inhibition, cessation, and modulation through analgesic therapy.
- Assess the various routes of delivery, delivery systems, dosage forms, and dispensing mechanisms used in analgesic therapy, adjunct therapy, supplementation, and specific aspects of lifestyle management.
- Select therapeutic alternatives for specific classifications related to analgesic therapy, specifically formulations that may be prescribed or used by the physician in the treatment of nociception, neuropathology, neuromas, centralization, direct and indirect consequences of vascular deprivation, neural budding, and plasticity.
- Evaluate comprehensive patient assessment chart data, including prior medical history, familial history, differential diagnoses, lifestyle behaviors, signs and symptoms, laboratory test results, analgesic-related medication, and adjunct pharmacotherapeutic and supplementation treatments, to enhance patient safety.
An unrestricted educational grant has been provided by MEDISCA Inc.
MIGUEL DE LA GARZA, MD, DABA, DAPM
Diplomate of the American Board of Pain Medicine, Diplomate of the American Board of Anesthesiology
Disclosure: Medisca Consultant
Dr. de la Garza is a board certified physician who practices multidisciplinary interventional pain management in four offices in the Tampa Bay area. He performs interventional pain procedures, specializing in minimally invasive surgical decompression of herniated discs and spinal stenosis, implantable intrathecal pumps, spinal cord stimulation, and peripheral nerve stimulation. Dr. de la Garza has published numerous research papers and abstracts, and has presented at regional and national academic conferences on the topics of anesthesia and pain medicine. He is also a consultant for numerous pharmaceutical and medical device manufacturers.
Dr. de la Garza received a Bachelor of Science in Molecular Biology and a Bachelor of Arts in Chemistry from Texas Lutheran College in Seguin, Texas. He graduated from the University of Texas Southwestern Medical School in 2001 and performed his anesthesia residency at the University of South Florida College of Medicine, Department of Anesthesiology and Critical Care from 2001 to 2005. He then completed an interventional pain medicine fellowship at The Cleveland Clinic, in the Department of Anesthesia and Pain Management.
KEN SPEIDEL, BS Pharm, PharmD, RPh, FIACP, FACA
Senior Associate, Gates Healthcare Associates
Disclosure: Accreditation Commission for Health Care (ACHC) Surveyor; Gates Healthcare Associates Consultant; MEDISCA Consultant
Dr. Ken Speidel is known for his experience in pharmacy practice and education, including his national recognition as a pharmacotherapeutic specialist in endocrinologyand pain management, as well expertise in sterile and non-sterile compounding processes. He has been instrumental in the development of national standards for pharmacy compounding practices and provides consulting services to many organizations including boards of pharmacy as well as hospitals and health systems in the United States and abroad.
Concurrent with his worldwide consulting and educational work, Dr. Speidel recently retired as a Professor of Pharmacy Practice. He has also assisted in the development and facilitation of many nationally recognized ACPE educational programs. Moreover, Ken was an advisor for the development of the Pharmacy Compounding Accreditation Board (PCAB) and remains an active surveyor and accreditation expert for PCAB/ACHC (Accreditation Commission for Health Care). He has also served as president of the National Home Infusion Association (NHIA) as well as president of large hospice program in the United States.
Dr. Speidel received a Bachelor of Science and Doctor of Pharmacy from Ohio Northern University. He has been awarded Fellowship status with the International Academy of Compounding Pharmacists as well as the American College of Apothecaries.
Total CPE Credits (home study and live activity): 25 CPE Hours = 2.5 CEUs
Joint Accreditation Status (University of Florida College of Pharmacy / LP3 Network)
Live activity type: Practice-based
To receive CPE credits for the home study, participants must complete a learning assessment with a score of 70% and submit a completed evaluation to the University of Florida College of Pharmacy. To receive CPE credits for the live activity, participants must demonstrate full and satisfactory participation, and submit a completed evaluation to the University of Florida College of Pharmacy.
Participants registered in the United States can obtain a statement of credit from their NABP e-profile. The University of Florida College of Pharmacy will report CPE credits to the CPE Monitor. Participants registered other than in the United States will receive a statement of credit by mail.
International participants should verify with their respective governing board for accreditation equivalency.
A written request must be sent to LP3 Network requesting “Cancellation without Transfer” to an alternate live activity date. If cancellation occurs at greater than or equal to 31 days from the live activity date, then the registrant will receive a 75% refund; 15-30 days a 50% refund; and less than or equal to 14 days no refund. There are no refunds, returns, or transfers upon purchase of the home study.
The transfer policy is only in effect if requested greater than or equal to 14 days prior to the original live activity date. Failure to submit the “Transfer Request” at least 14 days prior to the original live activity date will default to the “Cancellation and Refund Policy”. The transfer policy can only be applied one (1) time. Transfer to a new live activity date must be within the current calendar year. Failure to attend the new live activity will result in no refund and will no longer be transferable. Confirmation of the new activity date is subject to approval by LP3 Network based on the number of available seats within the selected live activity. There are no refunds, returns, or transfers upon purchase of the home study.
Date & Time: 5-6pm, Saturday, September 17th
Location: Hilton Toronto Airport Hotel & Suites, Mavis Boardroom
This is an excellent networking opportunity to meet with other professional pharmacists and physicians in the compounding industry, as well as the LP3 Network staff, in a fun and relaxed environment! Please RSVP by sending us a quick email by September 7th if you are interested in joining us.
We hope to see you there!
Use coupon code 20LP316 upon checkout to receive 20% off this educational training.